Evaluation of a bone marrow dysmyelopoiesis immunophenotypic index for the diagnosis and prognosis of myelodysplastic syndromes.

EVALUATION OF A BONE MARROW DYSMYELOPOIESIS IMMUNOPHENOTYPIC INDEX FOR THE DIAGNOSIS AND PROGNOSIS OF MYELODYSPLASTIC SYNDROMES. Cardiovasc Hematol Disord Drug Targets. 2015 Jun 30; Authors: Verigou E, Lampropoulou P, Smyrni N, Kolliopoulou G, Sakellaropoulos G, Starakis I, Zikos P, Solomou E, Symeonidis A, Karakantza M Abstract BACKGROUND: Myelodysplastic Syndromes (MDS) are a group of clonal hematopoietic stem cell disorders with significant heterogeneity in their clinical presentation and the prognosis of the patients. Several attempts have been made to incorporate flow cytometry (FC) findings into the diagnostic and/or prognostic criteria of dysplasia, but bone marrow (BM) aspirate morphology evaluation remains the gold-standard for diagnosis. The purpose of this study was to provide a diagnostic tool for MDS that relies on BM immunophenotyping and objectifies the interpretation of FC analysis and to validate its capacity to discriminate MDS from other causes of cytopenias. METHODS: To that purpose, a mathematical formula was developed which incorporates granulocytic maturation markers and the percentage of selected myeloid populations and translates them into a single parameter that quantifies the maturation and differentiation defects of BM granulocytes, named Dysmyelopoiesis Index (DMI). Bone marrow samples from 84 MDS patients and 47 non-MDS cytopenic patients were analyzed with FC and DMI was calculated for every patient. RESULTS: DMI det...
Source: Cardiovascular and Hematological Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Related Links:

Publication date: Available online 3 December 2019Source: Best Practice &Research Clinical HaematologyAuthor(s): Kristen B. McCullough, Mrinal M. PatnaikAbstractOptimal treatment for myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes remain to be defined and are currently extrapolated from MDS and MPN. The heterogeneity of these diseases and their rare occurrences add to this void. Supportive care therapies such as erythropoiesis stimulating agents, iron chelation and cytoreductive therapy do not have prospective evidence in these disorders and the only approved treatments, hypomethylating...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Purpose of review Since 2016, the WHO has recognized the significant phenotypic heterogeneity of chronic myelomonocytic leukemia (CMML) as a myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap disease. Although sharing many somatic mutations with MDS and MPN, the purpose of this review is to put recent biological findings of CMML in the context of evolutionary theory, highlighting it as a distinct evolutionary trajectory occurring in the context of clonal hematopoiesis. Recent findings Clonal hematopoiesis of indeterminate potential (CHIP), with a mutational spectrum and prevalence correlated with a...
Source: Current Opinion in Hematology - Category: Hematology Tags: MYELOID BIOLOGY: Edited by David C. Dale Source Type: research
AbstractPurpose of ReviewGenetic sequencing in myelodysplastic syndrome (MDS) has provided an improved understanding of the complexity and heterozygosity of the disease. More importantly, our molecular understanding of MDS is leading to rapid advancements and personalized therapy for our patients. Herein, we review the current mutation-driven treatment landscape in MDS, first focusing on individual mutations. We then discuss the effect of specific gene mutations on response and outcomes to standard therapies as well as to cutting edge investigational therapies.Recent FindingsMolecular annotation of MDS can predict response...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Conclusion: BOS is a high mortality complication that appears in a 15% of allogeneic HCT. Its management must be multidisciplinary because It may develops alone or associated with other organs disease. Respiratory function tests are necesary in extrapulmonary GVHD cases, as well as in patients with respiratory symptoms to detect premature pulmonary involvement and to establish early treatment.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Clinical Problems Source Type: research
In this study, we analyzed a well-defined consecutive series of 98 patients with acute myelogenous leukemia/myelodysplastic syndrome (AML/MDS) who received allogeneic stem cell transplantation with non-myeloablative (NMA) conditioning to determine risk factors associated with the severity of cGVHD. cGVHD was defined according to the 2005 National Institute of Health consensus criteria. Transfusions before transplantation, presence of HLA antibodies, composition of the graft (CD3+, CD19+, CD34+ cells), sibling or matched unrelated donor, female donor to male recipient, CMV serology and the development of acute GVHD (aGVHD),...
Source: Human Cell - Category: Cytology Source Type: research
The evolution of Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) as a treatment modality has witnessed the cure of several haematological conditions such as leukaemia, lymphoma, multiple myeloma, myelodysplastic syndromes, thalassaemia and aplastic anaemia [1]. The many advances made in this domain, and the availability of excellent post transplant care have ensured increased longevity in recipients of allo-HSCT. It has been demonstrated in previous studies that patients who are disease-free at five years after HSCT have a 10-year survival rate that exceeds 80% [2].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
The evolution of allogeneic hematopoietic stem cell transplant (allo-HSCT) as a treatment modality has witnessed the cure of several hematologic conditions such as leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, thalassemia, and aplastic anemia [1]. The many advances made in this domain and the availability of excellent post-transplant care have ensured increased longevity in recipients of allo-HSCT. It has been demonstrated in previous studies that patients who are disease free at 5 years after HSCT have a 10-year survival rate that exceeds 80% [2].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
We report an 18-year-old female with a 7-year history of BD. Colonoscopy demonstrated a huge ulcer in the cecum. Chromosomal examination revealed a karyotype of trisomy 8 in 87% of cells. Bone marrow examination revealed dysplastic cells in multilineages. Diagnoses: A diagnosis of intestinal BD associated with MDS accompanying trisomy 8 was made. Interventions: The patient underwent ileocecal resection due to microperforations of ileocecal ulcers; she then underwent allogeneic peripheral blood stem cell transplantation (PBSCT) with her mother as a donor. Outcomes: After the PBSCT, the patient's symptoms due to BD ...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Granulocyte colony-stimulating factor (G-CSF), a growth factor for neutrophils, has been successfully used for stem cell mobilization and T cell immune tolerance induction. The establishment of G-CSF-primed unmanipulated haploidentical blood and marrow transplantation (The Beijing Protocol) has achieved outcomes for the treatment of acute leukemia, myelodysplastic syndrome, and severe aplastic anemia with haploidentical allografts comparable to those of human leukocyte antigen (HLA)-matched sibling donor transplantation. Currently, G-CSF-mobilized bone marrow and/or peripheral blood stem cell sources have been widely used ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Cardiology | Cardiovascular | Drugs & Pharmacology | Heart | Hematology | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Study